Biofrontera (BFRI) Liabilities and Shareholders Equity (2020 - 2025)

Biofrontera's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $28.6 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 29.24% year-over-year to $28.6 million; the TTM figure through Dec 2025 stood at $80.7 million (down 6.98% YoY), while the FY2025 annual figure was $28.6 million, up 29.24% from the prior year.
• Liabilities and Shareholders Equity was $28.6 million for Q4 2025 at Biofrontera, up from $15.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $55.1 million in Q3 2022 to a low of $15.4 million in Q3 2021.
• Historically, Liabilities and Shareholders Equity has averaged $32.3 million across 5 years, with a median of $27.9 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 258.6% in 2022, then plunged 45.71% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $53.2 million in 2021, then slipped by 4.39% to $50.9 million in 2022, then tumbled by 45.11% to $27.9 million in 2023, then declined by 20.88% to $22.1 million in 2024, then grew by 29.24% to $28.6 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $28.6 million (Q4 2025), $15.4 million (Q3 2025), and $20.1 million (Q2 2025), per Business Quant data.